Beijing-based EdiGene Inc. has raised an additional $10 million as part of a pre-B investment financing. Led by Green Pine Capital Partners, which focuses on biotech and other IP-rich investments, EdiGene is developing genome-editing technologies into therapeutics for genetic diseases and cancer. Additional investors in this round include IDG Capital and Lilly Asia Ventures. Founded in 2015, EdiGene maintains subsidiaries in China’s Guangzhou and Cambridge, MA. EdiGENE Corporation is an emerging biotech company focusing on developing transformative therapeutics for unmet medical needs using its proprietary technologies on CRISPR and protein engineering platforms. The founder is Peking University professor Wensheng Wei. He has published more than 30 papers—8 among which are published by Cell or Nature publishing group, and 19 of these research papers involve genome editing.